Umoja Biopharma宣布超额认购1亿美元的C轮融资，以通过关键的肿瘤学临床里程碑推进体内CAR T管道-动脉网

Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones

vcaonline 等信源发布 2025-01-14 23:27



可切换为仅中文







Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones

Umoja Biopharma宣布超额认购1亿美元的C系列融资，以通过关键的肿瘤学临床里程碑推进体内CAR T管道

Series C financing co-led by Double Point Ventures and DCVC Bio

由Double Point Ventures和DCVC Bio联合牵头的C系列融资

Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells

继续支持VivoVec™衍生的体内CAR T细胞的临床开发

SEATTLE, January 14, 2025-- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The financing was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors..

西雅图，2025年1月14日——旨在实现CAR T细胞全面覆盖和承诺的体内细胞疗法临床阶段领导者Umoja Biopharma，Inc.（Umoja）今天宣布关闭1亿美元的C系列融资。融资由Double Point Ventures和DCVC Bio共同领导，新的和现有的投资者参与，包括ARK Investment、Cormorant Asset Management、MPM Capital、Qiming Venture Partners USA、RTW Investments、Alexandria Venture Investments、SoftBank Vision Fund 2、CaaS Capital、Yosemite管理的Emerson Collective Investments、K2 HealthVentures、骨髓瘤投资基金、明尼苏达大学捐赠基金以及其他著名的生命科学投资者。。

The proceeds from this financing will enable Umoja to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies.

这笔资金的收益将使Umoja能够推进其体内CAR T细胞治疗管道，包括其在多种肿瘤学和自身免疫临床研究中的领先CD22 UB-VV400项目。

In conjunction with the Series C financing, Umoja’s Board of Directors is pleased to welcome Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, as a new Board member.

结合C系列融资，Umoja董事会很高兴欢迎Double Point Ventures高级顾问Campbell Murray医学博士成为新的董事会成员。

“It is an honor to co-lead this transformative investment round and to join Umoja’s Board of Directors,” stated Dr. Murray. “Umoja’s groundbreaking work on in vivo CAR T cell therapies represents a new frontier in oncology and autoimmune treatment. The company’s innovation and leadership team position them at the forefront of this field, with the potential to significantly impact patients’ lives.

默里博士表示：“很荣幸能共同领导这一变革性投资回合，并加入“团结”的董事会。”。“Umoja在体内CAR T细胞疗法方面的开创性工作代表了肿瘤学和自身免疫治疗的新前沿。该公司的创新和领导团队将其置于该领域的前沿，有可能对患者的生活产生重大影响。

I look forward to collaborating with Umoja’s exceptional team, investor base, and Board to advance these pioneering programs through clinical development and beyond.”.

我期待着与Umoja杰出的团队、投资者基础和董事会合作，通过临床开发和其他方式推进这些开创性项目。”。

“We are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognize Umoja’s potential to develop the industry’s first in vivo CAR T cell generating therapies—all in the hopes of increasing effectiveness, reducing barriers, and expanding access to CAR T cell therapies,” commented Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma..

“我们很高兴地宣布，在新的和现有的投资者的大力支持下，我们的C系列融资已经结束，他们认识到Umoja有潜力开发业界第一种体内产生CAR T细胞的疗法，所有这些都是为了提高疗效，减少障碍，扩大获得CAR T细胞疗法的机会，”Umoja Biopharma联合创始人兼首席执行官安德鲁·沙伦伯格（AndrewScharenberg）医学博士评论道。。

Additionally, Dr. Phil Low of Purdue University transitioned to Board Observer and Chair of Umoja’s Scientific Advisory Board.

此外，普渡大学的Phil Low博士过渡为董事会观察员和“团结”科学顾问委员会主席。

Scott Myers, chairman of Umoja’s Board of Directors, added “This Series C fundraise demonstrates both the progress and significant potential of Umoja’s in vivo oncology programs including UB-VV400 and UB-VV111. Generating CAR T cells directly in vivo is the future of immunotherapy treatment, bringing the hope and promise of CAR T cell therapies to more patients without the burdens of long delays, supply chain constraints, and the toxicities associated with lymphodepleting chemotherapy.”.

“团结”董事会主席斯科特·迈尔斯（ScottMyers）补充道：“这场C系列募款活动证明了“团结”体内肿瘤学项目（包括UB-VV400和UB-VV111）的进展和巨大潜力。直接在体内产生CAR T细胞是免疫疗法治疗的未来，为更多患者带来了CAR T细胞疗法的希望和希望，而没有长时间延迟，供应链限制以及与淋巴消耗化疗相关的毒性。”。

About Umoja Biopharma

关于Umoja Biopharma

Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease.

Umoja Biopharma，Inc.是一家临床阶段生物技术公司，旨在开发体内细胞疗法，以改善CAR T细胞疗法在肿瘤学和自身免疫中的作用，有效性和可及性。Umoja的VivoVec™体内基因传递技术使患者自身的免疫系统能够抵抗疾病。

Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives.

使其核心技术得以实现的是该公司位于科罗拉多州路易斯维尔的最先进的慢病毒载体开发和制造设施。Umoja相信，它的方法可以提供更广泛的途径，提高最先进的免疫疗法的有效性，使更多的患者能够过上更好、更充实的生活。

To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/..

要了解更多信息，请在LinkedIn上与Umoja联系并访问http://umoja-biopharma.com/..

Contact:

联系人：

Investors

投资者

Grace Kim, PhD

Grace Kim博士

Head of Investor Relations

投资者关系主管

grace.kim@umoja-biopharma.com